Cambridge Neuroscience
Executive Summary
Former Warner-Lambert exec Elkan Gamzu, PhD, named to new position of VP-development of the CNS drug R&D firm, effective Oct. 1. Gamzu led the Tacrine (THA) clinical trials while at W-L, where he was VP-drug development for Parke-Davis. Gamzu will continue to handle the Tacrine development. He has agreed to stay on as a consultant until the NDA filing for the Alzheimer's drug. Fred Hershenson, PhD, succeeds Gamzu at Parke-Davis. He has been with Warner-Lambert seven years, most recently as senior director in charge of CNS chemistry.